Advisory Committee on Immunization Practices (ACIP), 59317-59318 [2020-20705]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 85, No. 183 / Monday, September 21, 2020 / Notices
petitions to add classes of workers to the
Special Exposure Cohort (SEC).
In December 2000, the President
delegated responsibility for funding,
staffing, and operating the Advisory
Board to HHS, which subsequently
delegated this authority to CDC. NIOSH
implements this responsibility for CDC.
The charter was issued on August 3,
2001, renewed at appropriate intervals,
and rechartered under Executive Order
13889 on March 22, 2020, and will
terminate on March 22, 2022.
Purpose: The Advisory Board is
charged with (a) providing advice to the
Secretary, HHS, on the development of
guidelines under Executive Order
13179; (b) providing advice to the
Secretary, HHS, on the scientific
validity and quality of dose
reconstruction efforts performed for this
program; and (c) upon request by the
Secretary, HHS, advise the Secretary on
whether there is a class of employees at
any Department of Energy facility who
were exposed to radiation but for whom
it is not feasible to estimate their
radiation dose, and on whether there is
reasonable likelihood that such
radiation doses may have endangered
the health of members of this class.
SDRR was established to aid the
Advisory Board in carrying out its duty
to advise the Secretary, HHS, on dose
reconstruction.
Matters to be Considered: The agenda
will include discussions on the
following dose reconstruction program
quality management and assurance
activities: Dose reconstruction cases
under review from Set 28, possibly
including cases involving, Oak Ridge
Gaseous Diffusion Plant (K25), Y–12
Plant, and Savannah River Site (SRS)
and potentially other Department of
Energy and Atomic Weapons Employers
facilities; Dose reconstruction cases
under review from Set 25, possibly
including cases involving, Hooker
Electrochemical, Nuclear Metals Inc.,
West Valley Demonstration Project,
Carborundum, Metals and Controls Corp
and potentially other Department of
Energy and Atomic Weapons Employers
facilities; and Dose reconstruction cases
under review from Set 27, possibly
including cases involving, Oak Ridge
Gaseous Diffusion Plant (K25), Paducah
Gaseous Diffusion Plant, SRS and
potentially other Department of Energy
and Atomic Weapons Employers
facilities.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
VerDate Sep<11>2014
19:59 Sep 18, 2020
Jkt 250001
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–20706 Filed 9–18–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2020–0100]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment. The meeting will be webcast
live via the World Wide Web.
DATES: The meeting will be held on
October 28–29, 2020 from 10:00 a.m. to
5:30 p.m., EDT (times subject to
change).
Written comments must be received
on or before October 29, 2020.
ADDRESSES: For more information on
ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/
index.html.
You may submit comments, identified
by Docket No. CDC–2020–0100 by any
of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Docket No. CDC–2020–0100,
c/o Attn: October ACIP Meeting, Centers
for Disease Control and Prevention,
1600 Clifton Road NE, MS H24–8,
Atlanta, GA 30329–4027.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
59317
documents or comments received, go to
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, GA 30329–
4027; Telephone: 404–639–8367; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: Purpose:
The committee is charged with advising
the Director, CDC, on the use of
immunizing agents. In addition, under
42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
Matters to be Considered: The agenda
will include discussions on COVID–19
vaccines, CDC immunization schedules,
seasonal influenza vaccines,
pneumococcal vaccines, orthopoxvirus
vaccine, dengue vaccine, recombinant
zoster vaccine, rabies vaccines, and
tickborne encephalitis vaccine. A
recommendation vote on the CDC
immunization schedules is scheduled.
Agenda items are subject to change as
priorities dictate. For more information
on the meeting agenda visit https://
www.cdc.gov/vaccines/acip/meetings/
meetings-info.html.
Meeting Information: The meeting
will be webcast live via the World Wide
Web; for more information on ACIP
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Comments received are part of the
public record and are subject to public
disclosure. Do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
E:\FR\FM\21SEN1.SGM
21SEN1
59318
Federal Register / Vol. 85, No. 183 / Monday, September 21, 2020 / Notices
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
CDC does not accept comment by email.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the October ACIP
meeting must submit a request at https://
www.cdc.gov/vaccines/acip/meetings/
no later than 11:59 p.m., EDT, October
21, 2020 according to the instructions
provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by October 22, 2020. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
Written Public Comment: Written
comments must be received on or before
October 29, 2020. Written public
comments submitted by 72 hours prior
to the ACIP meeting will be provided to
ACIP members before the meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–20705 Filed 9–18–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
Administration for Children and
Families
Submission for OMB Review; Family
Level Assessment and State of Home
Visiting (FLASH–V) Outreach and
Recruitment Study (New Collection)
Office of Planning, Research,
and Evaluation, Administration for
Children and Families, HHS.
ACTION: Request for public comment.
AGENCY:
The Administration for
Children and Families (ACF) Office of
Planning, Research, and Evaluation is
requesting public comment on new data
collection activities to gather
information about how Maternal, Infant,
and Early Childhood Home Visiting
(MIECHV) state and territory local
implementing agencies (LIAs) and tribal
grantees recruit families for program
participation and work with their
community referral partners to recruit
families. The project is designed to
examine challenges programs
experience reaching caseload capacity
and promising strategies to address how
challenges might be overcome.
DATES: Comments due within 30 days of
publication. OMB must make a decision
about the collection of information
SUMMARY:
Description: The ACF Office of
Planning, Research, and Evaluation is
proposing a new information collection
to learn more about how MIECHVfunded home visiting programs recruit
families for home visiting services. The
voluntary study will include a national
survey of MIECHV-funded program
managers, semi-structured interviews
with program staff, and a review of
program outreach and recruitment
materials. This descriptive work will
capture how programs identify and
recruit families to home visiting
services. The study will also capture
how outreach and recruitment
challenges and accomplishments related
to capacity have changed since COVID–
19 and identify strategies programs have
used to address associated challenges.
The activities and products from this
project will help ACF and the Health
Resources and Services Administration
to identify actionable bottlenecks in the
outreach and recruitment process to
allow for the development and testing of
strategies to improve the delivery of
MIECHV funded services.
Respondents: MIECHV funded state,
territory, or tribal grantee
administrators; program administrators;
program managers; and frontline staff.
ANNUAL BURDEN ESTIMATES
Instrument
Total number
of respondents
Number of
responses per
respondent
56
779
120
1
1
1
jbell on DSKJLSW7X2PROD with NOTICES
Request for LIA Contact Information from MIECHV Leads
LIA Survey ...........................................................................
Interview Protocol Local Implementing Agency ...................
VerDate Sep<11>2014
19:59 Sep 18, 2020
Jkt 250001
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Average
burden hours
per response
E:\FR\FM\21SEN1.SGM
.25
.50
.75
21SEN1
Total burden
hours
14
390
90
Annual burden
hours
7
195
45
]]>Agencies
[Federal Register Volume 85, Number 183 (Monday, September 21, 2020)]
[Notices]
[Pages 59317-59318]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-20705]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2020-0100]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment. The meeting will be webcast live via the World Wide
Web.
DATES: The meeting will be held on October 28-29, 2020 from 10:00 a.m.
to 5:30 p.m., EDT (times subject to change).
Written comments must be received on or before October 29, 2020.
ADDRESSES: For more information on ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
You may submit comments, identified by Docket No. CDC-2020-0100 by
any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Docket No. CDC-2020-0100, c/o Attn: October ACIP
Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H24-8, Atlanta, GA 30329-4027.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MS-H24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8367;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Purpose: The committee is charged with
advising the Director, CDC, on the use of immunizing agents. In
addition, under 42 U.S.C. 1396s, the committee is mandated to establish
and periodically review and, as appropriate, revise the list of
vaccines for administration to vaccine-eligible children through the
Vaccines for Children (VFC) program, along with schedules regarding
dosing interval, dosage, and contraindications to administration of
vaccines. Further, under provisions of the Affordable Care Act, section
2713 of the Public Health Service Act, immunization recommendations of
the ACIP that have been approved by the Director of the Centers for
Disease Control and Prevention and appear on CDC immunization schedules
must be covered by applicable health plans.
Matters to be Considered: The agenda will include discussions on
COVID-19 vaccines, CDC immunization schedules, seasonal influenza
vaccines, pneumococcal vaccines, orthopoxvirus vaccine, dengue vaccine,
recombinant zoster vaccine, rabies vaccines, and tickborne encephalitis
vaccine. A recommendation vote on the CDC immunization schedules is
scheduled. Agenda items are subject to change as priorities dictate.
For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Meeting Information: The meeting will be webcast live via the World
Wide Web; for more information on ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Comments received
are part of the public record and are subject to public disclosure. Do
not include any information in your comment or supporting materials
that you consider confidential or inappropriate for public disclosure.
If you include your name, contact information, or other information
that identifies you in the body of your comments, that
[[Page 59318]]
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket. CDC does not accept comment by
email.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the October ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/acip/meetings/ no later than
11:59 p.m., EDT, October 21, 2020 according to the instructions
provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by October 22, 2020. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to 3 minutes, and each speaker
may only speak once per meeting.
Written Public Comment: Written comments must be received on or
before October 29, 2020. Written public comments submitted by 72 hours
prior to the ACIP meeting will be provided to ACIP members before the
meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-20705 Filed 9-18-20; 8:45 am]
BILLING CODE 4163-18-P
